Clinical Observation of Low Molecular Heparin in the Treatment of Cancer-associated Acute Pulmonary Thromboembolism / 中国药房

ABSTRACT

OBJECTIVE:To observe the clinical efficacy and safety of low molecular heparin in the treatment of cancer-associ-ated acute pulmonary thromboembolism(APTE). METHODS:42 patients with cancer-associated APTE were randomly divided into combination group and simple drug group. All patients were given anti-cancer conventional treatment. Based on it,simple drug group was treated with Low molecular heparin injection 0.1 ml/kg by subcutaneous injection after embolism,q12 h;based on the treatment in simple drug group,combination group was additionally treated with Warfarin sodium tablet initial dose was 3 mg after 1-3 d of treatment,orally,qd. The dosage of warfarin was adjusted based on the international normalized ratio(INR),when INR was 2-3 for continuous 2 days,low molecular heparin was stopped,only warfarin was orally gave. The treatment course was 3 months. The clinic data was observed,including clinical efficacy,and pulmonary arterial blood gas indexes [blood oxygen pressure (pO2)and blood carbon dioxide partial pressure(pCO2)] before and after treatment. The fatality rate,re-embolism rate and bleed-ing rate in 6 months were followed-up,and the incidence of adverse reactions was recorded. RESULTS:The total effective rate in simple drug group was significantly higher than combination group,re-embolism and fatality rate were significantly lower than com-bination group,the differences were statistically significant(P0.05). CONCLU-SIONSBased on conventional treatment,the low molecular heparin has better efficacy than sequential therapy in the treatment of APTE,with similar safety.